ClinicalTrials.Veeva

Menu

Choroidal Thickness in Glaucoma Patients and Healthy Controls

University of Zurich (UZH) logo

University of Zurich (UZH)

Status

Unknown

Conditions

Glaucoma Patients and Healthy Controls

Treatments

Device: Spectralis® SD-OCT, Heidelberg Engineering GmbH, H

Study type

Observational

Funder types

Other

Identifiers

NCT01293474
EDI-OCT

Details and patient eligibility

About

With the new software tool (EDI, enhanced depth imaging) of the Spectralis® spectral-domain optical coherence tomography (SD-OCT) it is possible to visualize and measure the choroidal thickness. In glaucoma a vascular component is known. Therefore a difference of choroidal thickness in glaucoma patients and healthy controls is proposed.

  • Trial with medical device

Enrollment

200 estimated patients

Sex

All

Ages

50+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria: for both groups (glaucoma study group and control group):

men and women of at least 50 years of age

for the glaucoma study group: diagnosis of primary open angle glaucoma (POAG)

Exclusion criteria: for both groups (glaucoma study group and control group):

  • less then 50 years of age
  • any pathology of the central retina
  • any optic nerve disorder other then glaucoma
  • retinal vascular disorder

for the glaucoma study group: other glaucoma diagnosis then primary open angle glaucoma

for the control group: any diagnosis of glaucoma

Trial design

200 participants in 2 patient groups

glaucoma patients
Description:
patients with diagnosis of primary open angle glaucoma
Treatment:
Device: Spectralis® SD-OCT, Heidelberg Engineering GmbH, H
control group
Description:
age matched healthy controls
Treatment:
Device: Spectralis® SD-OCT, Heidelberg Engineering GmbH, H

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems